Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
about
Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fracturesUpdate on denosumab in the management of postmenopausal osteoporosis: patient preference and adherenceA review of denosumab for the treatment of osteoporosisLong-term treatment of osteoporosis: safety and efficacy appraisal of denosumabA critical review of brand and generic alendronate for the treatment of osteoporosis.Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in SpainRisedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Health technology assessment in osteoporosis.Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures.Denosumab in osteoporosis.A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions.A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment.Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
P2860
Q26775797-32B76F14-FF7A-4F3D-AF85-AD59F6E843A3Q26778291-17D3470B-B3F9-4911-B563-143C769136B7Q27005894-CB267985-E709-4FB7-8B7E-C76CBC6C040CQ28727655-49165569-AC9A-468A-88F3-34CE85FFC9DBQ35059218-568BA927-52C3-49ED-A7E4-70031532DF5AQ35087883-6EE9E0D9-6108-4EC2-8F4B-BFB1D1D0C02EQ35678676-80FD976B-1712-4786-B7F5-DD165CB69796Q36965411-F6570313-6A8D-4793-8B8C-3429B254349AQ36997684-970ADB16-45BA-4E2B-A3BA-33301BE77A70Q37340602-4B468DAE-6C73-499F-BB3F-394CBE14913BQ37488814-2E3229AA-ED49-40B6-9738-A5387AACA5E1Q37639404-9CF1C987-5C6F-47D4-80E7-BBEDC1864BB3Q37998122-3C14CD7A-D74D-42A2-B976-402CCBE06EFDQ38080911-7D01EF64-6EBC-4780-B2F4-CF140DE3110AQ38155095-14D93FAE-00CE-40C1-89E1-C348D2F8B9A5Q38167352-C966B581-534F-4F75-B034-A1825A304D05Q38190449-8165BFA1-19F4-4ED1-B264-9D8D2CBA50ACQ38265934-11392863-7595-40AB-8799-AB7E9832C042Q38870159-92AF73C4-3AFC-4A97-A0B4-0DFE153AC9FEQ43725897-85C66942-000A-480F-91D9-C11BEF5D5884Q46899289-2D36F219-BEC2-4488-87BA-0C77E53A7375Q46933439-43B0253C-30DB-4567-B50A-CB5E9118C773
P2860
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Cost effectiveness of denosuma ...... osteoporotic women in Belgium.
@en
Cost effectiveness of denosuma ...... osteoporotic women in Belgium.
@nl
type
label
Cost effectiveness of denosuma ...... osteoporotic women in Belgium.
@en
Cost effectiveness of denosuma ...... osteoporotic women in Belgium.
@nl
prefLabel
Cost effectiveness of denosuma ...... osteoporotic women in Belgium.
@en
Cost effectiveness of denosuma ...... osteoporotic women in Belgium.
@nl
P2860
P1433
P1476
Cost effectiveness of denosuma ...... osteoporotic women in Belgium.
@en
P2093
Mickaël Hiligsmann
P2860
P304
P356
10.2165/11539980-000000000-00000
P577
2011-10-01T00:00:00Z
P6179
1000911218